Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Lessons from cholesterol-lowering trials

S C Smith1

  • 1Division of Cardiology, Center for Cardiovascular Disease, University of North Carolina, Chapel Hill 27599-7075, USA.

The American Journal of Medicine
|July 31, 1998
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The genomic landscape of familial glioma.

Science advances·2023
Same author

Genome sequencing reveals underdiagnosis of primary ciliary dyskinesia in bronchiectasis.

The European respiratory journal·2022
Same author

Proxy reporting of health-related quality of life for people with dementia: a psychometric solution.

Health and quality of life outcomes·2020
Same author

Psoas and Paraspinous Muscle Measurements on Computed Tomography Predict Mortality in European Americans with Type 2 Diabetes Mellitus.

The Journal of frailty & aging·2019
Same author

Synthesis, optical properties and theoretical modelling of discrete emitting states in doped silicon nanocrystals for bioimaging.

Nanoscale·2018
Same author

Fermi Level Determination for Charged Systems via Recursive Density of States Integration.

The journal of physical chemistry letters·2018
Same journal

GLP-1 Receptor Agonists and Age-related Macular Degeneration Risk in Diabetes or Non-diabetic Obesity: A Retrospective Cohort Study.

The American journal of medicine·2026
Same journal

Marijuana Use and Acute Myocardial Infarction: Mechanistic Insights, Clinical Implications, and Emerging Challenges.

The American journal of medicine·2026
Same journal

Cave Canem - Beware of the Dog.

The American journal of medicine·2026
Same journal

Risk Factors for 30-day Hospital Readmission After Hospital-at-Home Treatment of Acute Pyelonephritis.

The American journal of medicine·2026
Same journal

Mesenteric Panniculitis.

The American journal of medicine·2026
Same journal

Hypercalcemia and hyperferritinemia in a patient with Graves' disease disease.

The American journal of medicine·2026
See all related articles

Coronary artery disease (CAD) affects millions, but cholesterol-lowering therapies, like HMG-CoA reductase inhibitors, significantly reduce mortality. Wider adoption of these preventive treatments is crucial for better patient outcomes.

Area of Science:

  • Cardiology
  • Preventive Medicine
  • Pharmacology

Background:

  • Coronary artery disease (CAD) is a leading cause of morbidity and mortality, affecting over 13 million individuals.
  • CAD underlies approximately 2 million cases of congestive heart failure, contributing significantly to healthcare costs.
  • Current spending on preventive therapies for heart disease remains suboptimal despite proven benefits.

Purpose of the Study:

  • To highlight the effectiveness of cholesterol-lowering therapies in reducing cardiovascular mortality.
  • To emphasize the need for improved clinical application of findings from recent cholesterol-lowering trials.
  • To advocate for increased focus on primary and secondary prevention strategies in CAD management.

Main Methods:

  • Review of recent clinical trials on cholesterol-lowering therapies.

Related Experiment Videos

  • Analysis of current treatment patterns and goal attainment in patients with CAD.
  • Evaluation of the impact of HMG-CoA reductase inhibitors on cardiovascular events and healthcare utilization.

    • Main Results:

    • Cholesterol-lowering therapies, particularly HMG-CoA reductase inhibitors, significantly reduce mortality from cardiovascular events.
    • These therapies decrease the need for costly hospitalizations and revascularization procedures.
    • Less than half of CAD patients receive cholesterol-lowering therapy, and few achieve their low-density lipoprotein (LDL) cholesterol goals.

    Conclusions:

    • Cholesterol-lowering therapy is a critical component of managing coronary artery disease.
    • Clinicians must prioritize the implementation of evidence-based preventive strategies, including statin therapy.
    • Improving patient adherence and achieving LDL cholesterol targets are essential for reducing CAD-related morbidity and mortality.